Endo Pharmaceuticals has reported that the FDA has granted final approval of the company's new drug applications for its extended-release and immediate-release formulations of oxymorphone hydrochloride. The products will be marketed as Opana ER tablets and Opana tablets.
Opana ER is indicated for the relief of moderate-to-severe pain in patients requiring continuous opioid treatment for an extended period of time. Opana (the immediate-release version) is indicated for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate.
